Trial Profile
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs JZP 258 (Primary)
- Indications Idiopathic hypersomnia
- Focus Registrational; Therapeutic Use
- Sponsors Jazz Pharmaceuticals plc
- 23 Oct 2023 Results of exploratory, post-hoc analysis presented in the Jazz Pharmaceuticals Media Release.
- 31 May 2023 According to a Jazz Pharmaceuticals Inc media release, data from this trial will be presented at the SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS).
- 27 Apr 2023 Results assessing the effects of lower-sodium oxybate on 24-Hour total sleep presented at the 75th Annual Meeting of the American Academy of Neurology 2023.